Aethlon Medical Monitors Bundibugyo Ebola, Cites 400,000-to-1,000 Copies/mL Viral Reduction
Aethlon Medical is monitoring the Bundibugyo Ebola outbreak in DRC and Uganda and is prepared to engage regulators for investigational use of its Hemopurifier device. In 2014 emergency use, a 6.5-hour Hemopurifier treatment reduced Ebola viral load from 400,000 to 1,000 copies/mL and removed about 242 million virions.
1. Bundibugyo Ebola Outbreak Monitoring
Aethlon Medical is actively monitoring the Bundibugyo Ebola outbreak in the DRC and Uganda, where health authorities warn of cross-border transmission risks, and is prepared to engage global healthcare and regulatory bodies for potential investigational Hemopurifier deployment.
2. Hemopurifier Historical Emergency Use Data
In 2014, under emergency use at Frankfurt University Hospital, a single 6.5-hour Hemopurifier session reduced a patient’s Ebola viral load from approximately 400,000 to 1,000 copies per milliliter and removed about 242 million virions, after which the patient fully recovered.
3. Regulatory Status and Development Pathway
The Hemopurifier holds a U.S. FDA IDE supplement approved in January 2015 and Breakthrough Device designation for cancer and viral indications, and is developed under an open IDE framework allowing physician-directed emergency and compassionate-use procedures subject to institutional and regulatory oversight.